Novozymes' bioenergy unit exceeds consensus amid wide H1 setback

Novozymes' bioenergy unit was the company's only division to perform better than expected. Altogether, the group had to swallow a negative organic growth of 3 percent for the first half of 2019.

Photo: Keld Navntoft / Ritzau Scanpix

Log in to read our articles

Welcome to EnergyWatch. A part of our content is exclusive and reserved for our users.

Try EnergyWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles

Latest News


See all

See all